Click Here for 5% Off Your First Aladdin Purchase!

Sirukumab (anti-IL-6) - Primary antibody, specific to IL6, >95%, high purity, Human IgG1, INHIBITOR of Interleukin-6 inhibitor

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥95%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Species reactivity(Reacts with): Human
  • Isotype: Human IgG1
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab175656
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175656-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$69.90
Ab175656-1mg
1mg
In stock
$339.90
Ab175656-5mg
5mg
In stock
$869.90
Ab175656-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,379.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series
Accession#:P05231 Gene ID:3569 IL6

Basic Description

Product NameSirukumab (anti-IL-6) - Primary antibody, specific to IL6, >95%, high purity, Human IgG1
SynonymsInterleukin BSF 2 antibody; B cell differentiation factor antibody; B cell stimulatory factor 2 antibody; B-cell stimulatory factor 2 antibody; BSF 2 antibody; BSF-2 antibody; BSF2 antibody; CDF antibody; CTL differentiation factor antibody; Cytotoxic T c
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityIL6
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionINHIBITOR of Interleukin-6 inhibitor
Product Description

Sirukumab (anti-IL-6) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab (anti-IL-6) has the potential for active lupus nephritis research.

Product Properties

IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE144.58 kDa
Purification MethodProtein A purified
Purity>95%
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1194585-53-9

Images

Sirukumab (anti-IL-6) (Ab175656) - ELISA
Immobilized hu-IL-6 at 1.0 μg/mL can bind Sirukumab (anti-IL-6) (Ab175656) with the EC₅₀ of 45.55 ng/mL.

Sirukumab (anti-IL-6) (Ab175656) - SEC
The purity of Sirukumab (anti-IL-6) (Ab175656) is more than 95% verified by HPLC.

Associated Targets

IL6 Tclin Interleukin-6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot NumberCertificate TypeDateItem
ZJ23F1202212Certificate of AnalysisDec 28, 2023 Ab175656
ZJ23F1202211Certificate of AnalysisDec 28, 2023 Ab175656

Related Documents

References

1. Nishimoto N.  (2006)  Interleukin-6 in rheumatoid arthritis..  Curr Opin Rheumatol,  18  (3): (277-81).  [PMID:16582692]
2. Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM, Zhou H.  (2011)  Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study..  Br J Clin Pharmacol,  72  (2): (270-81).  [PMID:21392075]
3. Hepgul N, Cattaneo A, Agarwal K, Baraldi S, Borsini A, Bufalino C, Forton DM, Mondelli V, Nikkheslat N, Lopizzo N et al..  (2016)  Transcriptomics in Interferon-α-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression..  Neuropsychopharmacology,  41  (10): (2502-11).  [PMID:27067128]
4. Rovin BH, van Vollenhoven RF, Aranow C, Wagner C, Gordon R, Zhuang Y, Belkowski S, Hsu B.  (2016)  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis..  Arthritis Rheumatol,  68  (9): (2174-83).  [PMID:27110697]
5. Du Preez A, Leveson J, Zunszain PA, Pariante CM.  (2016)  Inflammatory insults and mental health consequences: does timing matter when it comes to depression?.  Psychol Med,  46  (10): (2041-57).  [PMID:27181594]
6. Young JJ, Bruno D, Pomara N.  (2014)  A review of the relationship between proinflammatory cytokines and major depressive disorder..  J Affect Disord,  169  (3): (15-20).  [PMID:25128861]
7. Money KM, Olah Z, Korade Z, Garbett KA, Shelton RC, Mirnics K.  (2016)  An altered peripheral IL6 response in major depressive disorder..  Neurobiol Dis,  89  (3): (46-54).  [PMID:26804030]
8. Zhang C, Wu Z, Zhao G, Wang F, Fang Y.  (2016)  Identification of IL6 as a susceptibility gene for major depressive disorder..  Sci Rep,  (3): (31264).  [PMID:27502736]
9. Sun Y, Wang D, Salvadore G, Hsu B, Curran M, Casper C, Vermeulen J, Kent JM, Singh J, Drevets WC et al..  (2017)  The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease..  Brain Behav Immun,  66  (3): (156-164).  [PMID:28676350]
10. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC.  (2003)  Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex..  Science,  300  (5628): (2101-4).  [PMID:12829785]
11. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al..  (2014)  Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling..  MAbs,  (3): (774-82).  [PMID:24670876]
12. Kang S, Tanaka T, Narazaki M, Kishimoto T.  (2019)  Targeting Interleukin-6 Signaling in Clinic..  Immunity,  50  (4): (1007-1023).  [PMID:30995492]
13. Q Y Chen.  (1992-09-01)  [Stable and efficient expression of human interleukin-6 cDNA in mammalian cells after gene transfer]..  Zhonghua zhong liu za zhi [Chinese journal of oncology],  14  ((5)): (340-344).  [PMID:1291290]
14. H C van Zaanen,R P Koopmans,L A Aarden,H J Rensink,J M Stouthard,S O Warnaar,H M Lokhorst,M H van Oers.  (1996-09-15)  Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop..  The Journal of clinical investigation,  98  ((6)): (1441-1448).  [PMID:8823310]
15. Kim D, Won HY, Hwang ES, Kim YK, Choo HP..  (2017)  Synthesis of benzoxazole derivatives as interleukin-6 antagonists..  Bioorg Med Chem,  25  (12): (3127-3134).  [PMID:28442260]
16. May, L T LT, Shaw, J E JE, Khanna, A K AK, Zabriskie, J B JB and Sehgal, P B PB..  (1991)  Marked cell-type-specific differences in glycosylation of human interleukin-6..  Cytokine,      [PMID:1883960]
17. Lütticken, C C, Krüttgen, A A, Möller, C C, Heinrich, P C PC and Rose-John, S S..  (1991)  Evidence for the importance of a positive charge and an alpha-helical structure of the C-terminus for biological activity of human IL-6..  FEBS letters,    (6):   [PMID:2037043]
18. Clogston, C L CL, Boone, T C TC, Crandall, B C BC, Mendiaz, E A EA and Lu, H S HS..  (1989)  Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor..  Archives of biochemistry and biophysics,      [PMID:2472117]
19. Ming, J E JE, Cernetti, C C, Steinman, R M RM and Granelli-Piperno, A A..  (1989)  Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium..  The Journal of molecular and cellular immunology : JMCI,      [PMID:2610854]
20. Tonouchi, N N, Miwa, K K, Karasuyama, H H and Matsui, H H..  (1989)  Deletion of 3' untranslated region of human BSF-2 mRNA causes stabilization of the mRNA and high-level expression in mouse NIH3T3 cells..  Biochemical and biophysical research communications,    (15):   [PMID:2789513]
21. Zilberstein, A A, Ruggieri, R R, Korn, J H JH and Revel, M M..  (1986)  Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines..  The EMBO journal,      [PMID:3023045]
22. Wong, G G GG, Witek-Giannotti, J J, Hewick, R M RM, Clark, S C SC and Ogawa, M M..  (1988)  Interleukin 6: identification as a hematopoietic colony-stimulating factor..  Behring Institute Mitteilungen,      [PMID:3266463]
23. Van Damme, J J and 5 more authors..  (1988)  Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6..  Journal of immunology (Baltimore, Md. : 1950),    (1):   [PMID:3279116]
24. Brakenhoff, J P JP, de Groot, E R ER, Evers, R F RF, Pannekoek, H H and Aarden, L A LA..  (1987)  Molecular cloning and expression of hybridoma growth factor in Escherichia coli..  Journal of immunology (Baltimore, Md. : 1950),    (15):   [PMID:3320204]
25. Hirano, T T and 9 more authors..  (1986)  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin..  Nature,      [PMID:3491322]
26. Yasukawa, K K and 6 more authors..  (1987)  Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene..  The EMBO journal,      [PMID:3500852]
27. May, L T LT, Helfgott, D C DC and Sehgal, P B PB..  (1986)  Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved..  Proceedings of the National Academy of Sciences of the United States of America,      [PMID:3538015]
28. Haegeman, G G and 5 more authors..  (1986)  Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts..  European journal of biochemistry,    (15):   [PMID:3758081]
29. Breton, J J and 8 more authors..  (1995)  Structure, stability and biological properties of a N-terminally truncated form of recombinant human interleukin-6 containing a single disulfide bond..  European journal of biochemistry,    (15):   [PMID:7851440]
30. Nishimura, C C, Watanabe, A A, Gouda, H H, Shimada, I I and Arata, Y Y..  (1996)  Folding topologies of human interleukin-6 and its mutants as studied by NMR spectroscopy..  Biochemistry,    (9):   [PMID:8555185]
31. Somers, W W, Stahl, M M and Seehra, J S JS..  (1997)  1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling..  The EMBO journal,    (3):   [PMID:9118960]
32. Xu, G Y GY and 6 more authors..  (1997)  Solution structure of recombinant human interleukin-6..  Journal of molecular biology,    (2):   [PMID:9159484]
33. Fishman, D D and 6 more authors..  (1998)  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis..  The Journal of clinical investigation,    (1):   [PMID:9769329]
34. Foster, C B CB and 11 more authors..  (2000)  An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus..  Blood,    (1):   [PMID:11001912]
35. Ota, N N and 8 more authors..  (2001)  A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density..  Journal of human genetics,      [PMID:11355017]
36. Chung, Hye Won HW and 8 more authors..  (2003)  Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women..  Journal of human genetics,      [PMID:12768442]
37. Nemeth, Elizabeta E and 6 more authors..  (2004)  IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin..  The Journal of clinical investigation,      [PMID:15124018]
38. Wolsk, Emil E, Mygind, Helene H, Grøndahl, Thomas S TS, Pedersen, Bente K BK and van Hall, Gerrit G..  (2010)  IL-6 selectively stimulates fat metabolism in human skeletal muscle..  American journal of physiology. Endocrinology and metabolism,      [PMID:20823453]
39. Ellingsgaard, Helga H and 20 more authors..  (2011)  Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells..  Nature medicine,    (30):   [PMID:22037645]
40. Taniguchi, Koji K and 17 more authors..  (2015)  A gp130-Src-YAP module links inflammation to epithelial regeneration..  Nature,    (5):   [PMID:25731159]
41. Tagliabracci, Vincent S VS and 14 more authors..  (2015)  A Single Kinase Generates the Majority of the Secreted Phosphoproteome..  Cell,    (18):   [PMID:26091039]
42. Larsen, Jakob Vejby JV and Petersen, Claus Munck CM..  (2017)  SorLA in Interleukin-6 Signaling and Turnover..  Molecular and cellular biology,    (1):   [PMID:28265003]

Solution Calculators